MedPath

Effectiveness of Modified Diaphragmatic Training for Gastroesophageal Reflux Disease Post Covid-19

Not Applicable
Completed
Conditions
GERD
Post COVID-19 Condition
Diaphragm Issues
Registration Number
NCT05833243
Lead Sponsor
Indonesia University
Brief Summary

The study titled "Effectiveness of Modified Diaphragmatic Training for Improving GERD-Q Score, Diaphragmatic Excursion, Maximum Inspiratory Pressure and Lung Function in Adults With Gastroesophageal Reflux Disease After Covid-19: a Single-blinded Randomized Control Trial" is a clinical trial that aimed to investigate the effectiveness of 4 weeks modified diaphragmatic training (MDT) compare with standard diaphragmatic training for improving GERD-Q score, diaphragmatic excursion, maximum inspiratory pressure, and lung function in adults with gastroesophageal reflux disease (GERD) after COVID-19. The trial was single-blinded and randomized, and it included a total of 50 participants. The results of the study showed that MDT was effective in improving GERD-Q score, diaphragmatic excursion, maximum inspiratory pressure, and lung function in adults with GERD after COVID-19.

Detailed Description

The study aims to investigate the effectiveness of modified diaphragmatic training compared with standard diaphragmatic training in adults with gastroesophageal reflux disease after covid-19. The design is a single-center in a national respiratory referral center in Indonesia, single-blinded randomized control trial. A central randomization center used computer-generated tables to allocate treatments. The study will involve a randomized controlled trial with a sample size of 50 adult patients with GERD after covid-19. Participants will be randomly assigned to either a modified diaphragmatic training group or a control group.

Four weeks of training with diaphragmatic training followed by modified diaphragmatic training (MDT) or standard diaphragmatic training. Follow-up 30 days

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Male and female after recover from moderate COVID-19.
  • Six month post COVID-19
  • Age 18 to 60 years old
  • GERD-Q Score more than 7
  • Agree to participate in the study
  • Well understanding of the study procedure.
Exclusion Criteria
  • History of ventilator used while COVID
  • History of uncontrolled cardiac problems and chronic pulmonary
  • Pregnancy or lactation
  • History of surgery in the abdomen of the thoracic area
  • Severe scoliosis or Kyphotic
  • HIV/ AIDS, Autoimmune
  • Prolonged use of dyslipidemia drug more than 1 year
  • Prolonged use of prokinetic gastric drug more than 4 weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from baseline of GERD-Q Score after 4 weeksbase line and week 4

GERD was diagnosed when the GERD-Q score is above or equal with 8

Change from baseline of Diaphragmatic Excursion after 4 weeksbase line and week 4

The increase of diaphragm range of movement during inspiration and expiration

Change from baseline of Maximal Inspiratory Pressure after 4 weeksbase line and week 4

The maximal pressure of inspiratory muscle strength that related to diaphragm strength

Secondary Outcome Measures
NameTimeMethod
Change from baseline of Lung function (FEV1, FVC and ratio FEV1/FVC) after 4 weeksbase line and week 4

the improvement of FEV1, FVC and ratio FEV1/FVC

Trial Locations

Locations (1)

Faculty of Medicine, Universitas Indonesia

🇮🇩

Jakarta Pusat, DKI Jakarta, Indonesia

Faculty of Medicine, Universitas Indonesia
🇮🇩Jakarta Pusat, DKI Jakarta, Indonesia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.